Maxivanil (Vancomycin Hydrochloride)

Vancomycin binds to the D‑Ala‑D‑Ala terminus of peptidoglycan precursors, blocking the cross‑linking of the bacterial cell wall. This inhibition compromises cell wall integrity, leading to bacterial lysis and death, primarily against Gram‑positive organisms.

The dosing regimen for vancomycin is individualized by the prescriber based on infection type, severity, patient weight, renal function, and therapeutic drug monitoring results. Clinicians determine the appropriate dose and infusion rate for each patient.

Safety data for vancomycin in pregnancy and lactation are limited. It should be used only when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the Maxivanil product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Vancomycin is a first‑line agent for MRSA infections and is often compared with linezolid, daptomycin, or newer lipoglycopeptides. While vancomycin requires intravenous administration and therapeutic monitoring, alternatives may offer oral dosing or different safety profiles, but choice depends on infection site, severity, and patient factors.

Maxivanil should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to use, the product should be inspected for particulate matter and prepared under aseptic conditions according to the manufacturer’s instructions.

Maxivanil is administered intravenously, typically as an infusion over a period of 60‑120 minutes. The infusion rate may be adjusted based on patient tolerance, especially to reduce the risk of infusion‑related reactions such as Red Man syndrome.

The most serious adverse effects include nephrotoxicity, ototoxicity, severe allergic reactions (anaphylaxis), and thrombocytopenia. Patients receiving vancomycin should have renal function and hearing monitored regularly, and any signs of hypersensitivity should prompt immediate medical evaluation.

Maxivanil is contraindicated in patients with a known hypersensitivity to vancomycin or other glycopeptide antibiotics. Caution is also advised for individuals with pre‑existing severe renal impairment, hearing loss, or those receiving concurrent nephrotoxic or ototoxic medications.